Skip to main content
Premium Trial:

Request an Annual Quote

Cenix, Metanomics Reach Research Agreement

NEW YORK (GenomeWeb) – Contract research organization Cenix BioScience this week announced a research framework agreement with metabolite services and biomarker firm Metanomics Health.

As the first assignment, Cenix will perform a target validation project for Metanomics for an undisclosed disease indication. Cenix will use its expertise in high-content screening based on the Definiens XD image analysis platform for the comprehensive functional characterization of target genes designated by Metanomics, it said.

Financial and other terms of the deal were not disclosed.

Cenix has operations in Germany and the US and specializes in genome-scale gene modulation studies and high-throughput, high-content pharmacology. Metanomics, a BASF Group company based in Germany, provides metabolite profiling services and develops metabolomic biomarkers.

The Scan

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.

Survey Sees Genetic Literacy on the Rise, Though Further Education Needed

Survey participants appear to have higher genetic familiarity, knowledge, and skills compared to 2013, though 'room for improvement' remains, an AJHG paper finds.

Study Reveals Molecular, Clinical Features in Colorectal Cancer Cases Involving Multiple Primary Tumors

Researchers compare mismatch repair, microsatellite instability, and tumor mutation burden patterns in synchronous multiple- or single primary colorectal cancers.

FarGen Phase One Sequences Exomes of Nearly 500 From Faroe Islands

The analysis in the European Journal of Human Genetics finds few rare variants and limited geographic structure among Faroese individuals.